Статья

Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs [вариант вируса гриппа в, адаптированный к мышам, для изучения лечебной и профилактической Эффективности противовирусных препаратов in vitro и in vivo]

E. Prokopyeva, O. Kurskaya, M. Solomatina, I. Sobolev, T. Murashkina, A. Derko, K. Korchagina, A. Yunusova, A. Alekseev, A. Shestopalov, S. Sysolyatin, A. Vorozhtsov, O. Vaizova, E. Sherstoboev, K. Sharshov, A. Dygai,
2021

Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs. Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed comparative assessment of in vivo and in vitro pathogenicity of the parental virus and adapted influenza B virus. Was assessed inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and Tamiflu) in relation to the adapted influenza B virus. Results: adapted influenza B virus (B/ Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu®) on the model of influenza infection. Were proved the high efficiency of the innovative drug – oseltamivir ethoxysuccinate. Conclusion: the antigen-relevant adapted influenza B virus (В/Novosibirsk/40/2017-MA strain) can be used to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains. © 2019 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • E. Prokopyeva
    Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russian Federation
  • O. Kurskaya
    Novosibirsk State University, Novosibirsk, Russian Federation
  • M. Solomatina
    Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
  • I. Sobolev
    Dagestan State University, Makhachkala, Russian Federation
  • T. Murashkina
    Institute for Problems of Chemical and Energetic Technologies, Biysk, Russian Federation
  • A. Derko
    National Research Tomsk State University, Tomsk, Russian Federation
  • K. Korchagina
    Siberian State Medical University, Tomsk, Russian Federation
  • A. Yunusova
    Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg of Tomsk National Research Medical Center, Tomsk, Russian Federation
  • A. Alekseev
  • A. Shestopalov
  • S. Sysolyatin
  • A. Vorozhtsov
  • O. Vaizova
  • E. Sherstoboev
  • K. Sharshov
  • A. Dygai
Название журнала
  • Jurnal Infektologii
Том
  • 11
Выпуск
  • 4
Страницы
  • 53-64
Ключевые слова
  • antivirus agent; ethoxyacrylate; oseltamivir; sialidase inhibitor; unclassified drug; adaptation; animal experiment; animal model; animal tissue; Article; brain; clinical feature; controlled study; heart; in vitro study; in vivo study; infection prevention; influenza B; Influenza B virus; kidney; liver; lung; mouse; mouse model; nonhuman; pathogenicity; spleen; virus load
Издатель
  • Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR)
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus